Nasdaq
AnPac Bio Receives Nasdaq Delisting Notice
The Chinese cancer diagnostics firm plans to appeal the decision, which is related to a requirement that the firm maintain a minimum $2.5 million stockholders' equity.
Genetron Regains Compliance With Nasdaq Listing Requirement
The Chinese cancer molecular profiling firm had previously failed to meet the Nasdaq's minimum bid price requirement.
Sema4 Receives Nasdaq Noncompliance Warning, Will Return $42M Under Payor Lawsuit Settlement
The company's stock price had been below $1 per share for 30 trading days prior to the notice, which Sema4 received Dec. 28.
HTG Molecular Diagnostics to Implement Reverse Stock Split
Last month, the company reported a 48 percent year-over-year drop in third quarter revenues as it repositions itself as a developer of drug discovery technologies.
Centogene Gets Nasdaq Non-Compliance Notice
The company has 180 days from the date of the notice to regain compliance with the listing requirement, during which time it will continue to trade on the exchange.